ZIVO Bioscience, Inc. Enters Into Pilot Program to Expand Production Into Europe, Contracts With Algatek Asturias, S.L.

ZIVO Bioscience, Inc. Enters Into Pilot Program to Expand Production Into Europe, Contracts With Algatek Asturias, S.L.

KEEGO HARBOR, Mich., July 11, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that it has contracted with Algatek, S.L., the Spanish algae technology innovator, to conduct a pilot program using proprietary Algatek production technology. Algatek operates a fully-licensed food-pharma grade facility that will be able to certify ZIVO products and help streamline compliance in the Eurozone and Middle East regulatory environments, expanding potential markets for the Company’s offerings. 

Last week, Algatek successfully introduced the ZIVO strain into its production environment at the facility located in Asturias, Spain and will commence scale-up over the next few weeks, when it is expected to cultivate the ZIVO strain in its commercial-scale 96 meter photobioreactors.

About Algatek, S.L.

AAA Accelerator Group UK, Ltd, Hatfield UK, and its biotech subsidiary Algatek Asturias, S.L.; Teverga Asturias Spain, based in Asturias, Spain, have developed a proprietary algae photobioreactor technology that accelerates growth and boosts yield efficiency. The closed system is able to monitor and manipulate a wide range of cultivation parameters, and then replicate those conditions at commercial volume in full compliance with food and pharmaceutical production and safety standards.

About ZIVO Bioscience, Inc.

ZIVO Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.


Investor Relations
(248) 452 9866 ext 150
ZIVO Bioscience, Inc.    

Primary Logo

Source: Zivo Bioscience, Inc.